Drugs / SXR1096
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05211830 | Dec 2021 → Jun 2025 | Netherton syndrome | Sixera Pharma | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SXR1096 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05211830 ↗ |
| Action | Inhibit | “can inhibit the proteases kallikrein 5, 7 and 14” NCT05211830 ↗ |
| Modality | Small molecule | “specific small molecule inhibitor of KLK5, 7 and 14” NCT05211830 ↗ |
| Route | Topical | “topically applied SXR1096 cream” NCT05211830 ↗ |
| Target | KLK5 | “specific small molecule inhibitor of KLK5, 7 and 14” NCT05211830 ↗ |